Metronomic scheduling: The future of chemotherapy?

Lancet Oncology

Volumn 2, Issue 12, 2001, Pages 733-740

  Gasparini, Giampietro ^a,b  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b Division of Medical Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; CAMPTOTHECIN; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEFITINIB; GEMCITABINE; GROWTH FACTOR; MERCAPTOPURINE RIBOSIDE; METHOTREXATE; MONOCLONAL ANTIBODY; NIMESULIDE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE; SAFINGOL; TAXANE DERIVATIVE; TRASTUZUMAB; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ADULT; ANGIOGENESIS; ANIMAL CELL; BLOOD VESSEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM; ENDOTHELIUM CELL; EXPERIMENT; FEMALE; FREQUENCY ANALYSIS; FUTUROLOGY; GENETICS; HUMAN; INHIBITION KINETICS; MOLECULAR BIOLOGY; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TOXICITY; TREATMENT PLANNING; TUMOR CELL; TUMOR GROWTH;

EID: 0035214416     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00587-3     Document Type: Review

References (68)

1. Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules
2. Shifting the cancer paradigm: Must we kill to cure?
3. Vasculature and micro-environmental gradients: The missing links in novel approaches to cancer therapy?
4. Chemotherapeutic drugs: More really is not better
5. Pharmacogenetic applications of the Human Genome Project
6. Clinical strategies for cancer treatment: The role of drugs
7. Antiangiogenic scheduling of lower dose cancer chemotherapy
8. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for combination therapy
9. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
10. A cancer therapy resistant to resistance
11. Tumor angiogenesis: Past, present and the near future
12. The microenvironment of the tumour-host interface
13. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
14. Tumor angiogenesis: Therapeutic implications
15. The rationale and future potential of angiogenesis inhibitors in neoplasia
16. Angiogenesis: Pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs
17. Genes expressed in human tumor endothelium
18. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
19. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
20. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
21. Vascular attack as a therapeutic strategy for cancer
22. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphomas
23. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool
24. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studies in the mouse cornea model
25. Antiangiogenic potential of campthothecin and topotecan
26. Synthetic analogues of fumagallin that inhibit angiogenesis and suppress tumour growth
27. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process
28. Antiangiogenesis is produced by noncytotoxic doses of vinblastine
29. Role of interferons in the regulation of cell proliferation, differentiation, and development
30. Interferon-α-mediated downregulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
31. Differences in vascular response between primary and transplanted tumours
32. Angiogenic heterogeneity: Regulation of neoplastic angiogenesis by the organ microenvironment
33. Redefining the target: Chemotherapeutics as antiangiogenics
34. Taxol involution of collagen-induced arthritis: Ultrastructural correlation with the inhibition of synovitis and neovascularization
35. High-time chemotherapy or high time for low dose
36. Evolving concepts in the systemic drug therapy of breast cancer
37. Increased dose-density in small-cell lung cancer: A failed strategy?
38. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
39. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents
40. Does an improved control of tumor growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells?
41. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factors
42. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
43. Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors
44. Combinations for cancer prevention
45. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis
46. Cyclo-oxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines
47. Inhibitors of tyrosine kinase
48. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
49. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
50. Efficacy of cytotoxic agents against human tumor xenograft is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
51. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma
52. Acquired resistance to the antitumour effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis
53. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis
54. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
55. Phase I and pharmacological study of vinblastine by prolonged continuous infusion
56. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer
57. Thalidomide: An old sedative-hypnotic with anticancer activity?
58. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
59. Interferon α 2a therapy for life-threatening hemangiomas of infancy
60. Classification and diagnostic prediction of cancers using gene expression prolifing and artificial neural network
61. Integrating molecular medicine with functional proteomics: Realities and expectations
62. Molecular-targeted anticancer therapy: Challenges related to study-design and choice of proper end-points
63. Clinical trial designs for cytostatic agents: Are new approaches needed?
64. Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer
65. Phase I study of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
66. Angiostatin induces and sustains dormancy of human primary tumors
67. Survival without tumor shrinkage: Reevaluation of survival gain by cytostatic effect of chemotheraphy
68. Prolonged stable disease affects survival in patients with solid gastric tumor: Analysis of phase II studies of doxifluridine